Telaprevir Prospects Improve With Positive Findings In Twice-daily Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex reports trial data on hepatitis C candidate show twice-daily dosing efficacy, increased sustained virologic response.
You may also be interested in...
Market Likes Telaprevir For Twice-daily Dosing
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.
Market Likes Telaprevir For Twice-daily Dosing
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.
Vertex To Launch Phase III Trial Of Telaprevir In Treatment-failure HCV Patients
Biotech gets U.S. and EU approval to test HCV drug in full range of patients who failed in prior treatment.